These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 25263445)

  • 21. Modification of DBC1 by SUMO2/3 is crucial for p53-mediated apoptosis in response to DNA damage.
    Park JH; Lee SW; Yang SW; Yoo HM; Park JM; Seong MW; Ka SH; Oh KH; Jeon YJ; Chung CH
    Nat Commun; 2014 Nov; 5():5483. PubMed ID: 25406032
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulation of SUMOylation by reversible oxidation of SUMO conjugating enzymes.
    Bossis G; Melchior F
    Mol Cell; 2006 Feb; 21(3):349-57. PubMed ID: 16455490
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transient global cerebral ischemia induces a massive increase in protein sumoylation.
    Yang W; Sheng H; Warner DS; Paschen W
    J Cereb Blood Flow Metab; 2008 Feb; 28(2):269-79. PubMed ID: 17565359
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sumoylation at chromatin governs coordinated repression of a transcriptional program essential for cell growth and proliferation.
    Neyret-Kahn H; Benhamed M; Ye T; Le Gras S; Cossec JC; Lapaquette P; Bischof O; Ouspenskaia M; Dasso M; Seeler J; Davidson I; Dejean A
    Genome Res; 2013 Oct; 23(10):1563-79. PubMed ID: 23893515
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Fluorescent In Vitro Assay to Investigate Paralog-Specific SUMO Conjugation.
    Eisenhardt N; Chaugule VK; Pichler A
    Methods Mol Biol; 2016; 1475():67-78. PubMed ID: 27631798
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Spatiotemporal distribution of SUMOylation components during mouse brain development.
    Hasegawa Y; Yoshida D; Nakamura Y; Sakakibara S
    J Comp Neurol; 2014 Sep; 522(13):3020-36. PubMed ID: 24639124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systematic determinations of SUMOylation activation intermediates and dynamics by a sensitive and quantitative FRET assay.
    Song Y; Liao J
    Mol Biosyst; 2012 Jun; 8(6):1723-9. PubMed ID: 22466055
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of biochemically distinct properties of the small ubiquitin-related modifier (SUMO) conjugation pathway in Plasmodium falciparum.
    Reiter K; Mukhopadhyay D; Zhang H; Boucher LE; Kumar N; Bosch J; Matunis MJ
    J Biol Chem; 2013 Sep; 288(39):27724-36. PubMed ID: 23943616
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SUMO targets the APC/C to regulate transition from metaphase to anaphase.
    Eifler K; Cuijpers SAG; Willemstein E; Raaijmakers JA; El Atmioui D; Ovaa H; Medema RH; Vertegaal ACO
    Nat Commun; 2018 Mar; 9(1):1119. PubMed ID: 29549242
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mesenchymal Stem Cell Migration and Proliferation Are Mediated by Hypoxia-Inducible Factor-1α Upstream of Notch and SUMO Pathways.
    Ciria M; García NA; Ontoria-Oviedo I; González-King H; Carrero R; De La Pompa JL; Montero JA; Sepúlveda P
    Stem Cells Dev; 2017 Jul; 26(13):973-985. PubMed ID: 28520516
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modification of papillomavirus E2 proteins by the small ubiquitin-like modifier family members (SUMOs).
    Wu YC; Roark AA; Bian XL; Wilson VG
    Virology; 2008 Sep; 378(2):329-38. PubMed ID: 18619639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of the loss of SUMO pathway function on cancer cells and tumor proliferation.
    He X; Riceberg J; Pulukuri SM; Grossman S; Shinde V; Shah P; Brownell JE; Dick L; Newcomb J; Bence N
    PLoS One; 2015; 10(4):e0123882. PubMed ID: 25860128
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A mechanism for inhibiting the SUMO pathway.
    Boggio R; Colombo R; Hay RT; Draetta GF; Chiocca S
    Mol Cell; 2004 Nov; 16(4):549-61. PubMed ID: 15546615
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The ubiquitin-like modifier FAT10 interferes with SUMO activation.
    Aichem A; Sailer C; Ryu S; Catone N; Stankovic-Valentin N; Schmidtke G; Melchior F; Stengel F; Groettrup M
    Nat Commun; 2019 Oct; 10(1):4452. PubMed ID: 31575873
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The SUMO components in rheumatoid arthritis.
    Wu Q; Jiang Y; You C
    Rheumatology (Oxford); 2022 Nov; 61(12):4619-4630. PubMed ID: 35595244
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SUMO-mimicking peptides inhibiting protein SUMOylation.
    Zhao B; Villhauer EB; Bhuripanyo K; Kiyokawa H; Schindelin H; Yin J
    Chembiochem; 2014 Dec; 15(18):2662-6. PubMed ID: 25412743
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ubc9 negatively regulates BMP-mediated osteoblastic differentiation in cultured cells.
    Yukita A; Hosoya A; Ito Y; Katagiri T; Asashima M; Nakamura H
    Bone; 2012 May; 50(5):1092-9. PubMed ID: 22366399
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Profiles of SUMO and ubiquitin conjugation in an Alzheimer's disease model.
    McMillan LE; Brown JT; Henley JM; Cimarosti H
    Neurosci Lett; 2011 Sep; 502(3):201-8. PubMed ID: 21843595
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant reconstitution of sumoylation reactions in vitro.
    Flotho A; Werner A; Winter T; Frank AS; Ehret H; Melchior F
    Methods Mol Biol; 2012; 832():93-110. PubMed ID: 22350878
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Visfatin promotes cell and tumor growth by upregulating Notch1 in breast cancer.
    Park HJ; Kim SR; Kim SS; Wee HJ; Bae MK; Ryu MH; Bae SK
    Oncotarget; 2014 Jul; 5(13):5087-99. PubMed ID: 24970818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.